12.20.24
Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
(PAR-25-315)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): Not Applicable
Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
(PAR-25-316)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): Not Applicable
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
(PAR-25-321)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
(PAR-25-346)
National Cancer Institute
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): Multiple dates, see announcement
Integrating Mental Health Care into Health Care Systems and Non-Health Settings in Low- and Middle-Income Countries (R01 Clinical Trial Optional)
(PAR-25-201)
Application due date: Multiple dates, see announcement.
12.6.24
Gates Foundation - Grand Challenges Nigeria, entitled "Advancing Innovative Solutions for Maternal, Newborn and Child Health." The deadline for application is January 31, 2025.
Reminder: FORMS-I Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2025
(NOT-OD-25-026)
National Institutes of Health
Reminder that Multiple Changes Affecting Extramural Applications and Review are Coming for Application Due Dates on or After January 25, 2025
(NOT-OD-25-035)
National Institutes of Health
Updated Guidance on Salary Limitation for Grants and Cooperative Agreements
(NOT-OD-25-025)
National Institutes of Health
Notice of Special Interest (NOSI): Implementation Science for Climate Change and Health
(NOT-CA-25-003)
Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)
(PAR-25-242)
Application Receipt Date(s): Multiple dates, see announcement.
Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
(PAR-25-299)
National Institute on Minority Health and Health Disparities
National Institute on Alcohol Abuse and Alcoholism
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments
(NOT-CA-25-012)
National Cancer Institute
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
(PAR-25-167)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)
(PAR-25-177)
National Institute of Mental Health
Application Receipt Date(s): Multiple dates, see announcement.
Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 Clinical Trial Required)
(PAR-25-178)
National Institute of Mental Health
Application Receipt Date(s): Multiple dates, see announcement.
HIV Prevention and Alcohol (R34 Clinical Trials Optional)
(PAS-25-161)
National Institute on Alcohol Abuse and Alcoholism
Application Receipt Date(s): Not Applicable
HIV Prevention and Alcohol (R01 Clinical Trials Optional)
(PAS-25-208)
National Institute on Alcohol Abuse and Alcoholism
Office of Disease Prevention
Application Receipt Date(s): Not Applicable
Notice of Intent to Publish a Funding Opportunity Announcement for NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34)
(NOT-DA-24-051)
National Institute on Drug Abuse
Notice of Intent to Publish a Funding Opportunity Announcement for NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01)
(NOT-DA-24-052)
National Institute on Drug Abuse
Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
(PAR-25-152)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
(PAR-25-243)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
(PAR-25-244)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
11.8.24
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
(PAR-25-144)
R03 (Clinical Trial Not Allowed) (PAR-25-233)
R21 (Clinical Trial Optional) (PAR-25-143)
Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries (LMICs) for Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed)
(RFA-AG-25-031)
Application due date: Multiple dates, see announcement.
2025-2026 CEGA Fellowship Program - CEGA invites researchers from East and West Africa interested in developing their skills in quantitative social science research (including impact evaluation) to apply for a 16-week, in-person fellowship at the University of California, Berkeley (offered both Fall 2025 and Spring 2026) or at Northwestern University (offered Spring 2026 only). For this call, interested applicants can apply to 1 of 3 research tracks: General Development Research, Early Childhood Development, or Youth Livelihoods
Deadline: January 17, 2025
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
(PAR-25-103)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
(PAR-25-104)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
(PAR-25-139)
National Cancer Institute
Application Receipt Date(s): Multiple dates, see announcement.
10.25.24
Melinda French Gates/ USAID announced $250 million global open call: Action for Women’s Health
Deadline to register: December 3, 2024, Deadline to submit applications January 10, 2024
New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)
(RFA-AI-24-068)
Application due date: January 31, 2025
NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
(PAR-25-078)
Application due date: Multiple dates, see announcement.
Co-infection and Cancer (R01 Clinical Trial Not Allowed) (PAR-25-082)
Application due date: Multiple dates, see announcement.
Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses funding opportunities:
- R21 - Clinical Trial Optional (PAR-25-115)
Application due date: Multiple dates, see announcement. - R01 - Clinical Trial Optional (PAR-25-116)
Application due date: Multiple dates, see announcement.
Funding Opportunities
10.11.24
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) (PAR-22-106)
Application due date: Multiple dates, see announcement.
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) (PAR-22-109)
Application due date: Multiple dates, see announcement.
NIAID Research Education Program Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed) Application due date: Multiple dates, see announcement.
Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional)
(NOT-OD-25-002)
Office of Disease Prevention
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
(PA-25-121)
National Cancer Institute
Application Receipt Date(s): February 05, 2025
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
(PA-25-123)
National Cancer Institute
Application Receipt Date(s): February 16, 2025
Funding Opportunities
9.27.24
Security and Development are launching the NIH/PEPFAR Local Implementation Science Network (LISN) Deadline November 4, 2024
Reminder: Reporting Data Management and Sharing (DMS) Plan Activities in Research Performance Progress Reports (RPPRs) Submitted on or After October 1, 2024
(NOT-OD-24-175)
National Institutes of Health
U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS)
(R01 Clinical Trial Optional) *See eligibility
(RFA-AI-24-023)
National Institute of Allergy and Infectious Diseases
National Institute on Alcohol Abuse and Alcoholism
National Cancer Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
Office of AIDS Research
Application Receipt Date(s): March 12, 2025
Funding Opportunities
9.13.24
The 15th African Society of Human Genetics Conference. Entebbe, Uganda Feb 03-07, now accepting abstracts.
NIH Grants Policy Updates: FY2025 Edition - Registration Open for October 17, 2024 Webinar
(NOT-OD-24-170)
Office of the Director, NIH
Notice of Special Interest (NOSI): Career Development Opportunities for Research on Cancer in Global Settings at the Center for Global Health at the National Cancer Institute
(NOT-CA-24-098)
National Cancer Institute
Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries (LMICs) for Aging and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed)
(RFA-AG-25-031)
National Institute on Aging
Application Receipt Date(s): Multiple dates, see announcement.
Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed)
(RFA-AG-25-032)
National Institute on Aging
Application Receipt Date(s): Multiple dates, see announcement.
Funding Opportunities
8.29.24
The American Association of University Women (AAUW) is accepting applications for International Fellowships. Fellowships are awarded for full-time study or research in the United States to women who are not U.S. citizens or permanent residents.
*see eligibility requirements
Application deadline: November 15, 2024
Retirement of NIHs Automated Just-in-Time Email Notification
(NOT-OD-24-165)
National Institutes of Health
Notice of NIH Participation in the Ecology and Evolution of Infectious Diseases Program
(NOT-TW-24-009)
John E. Fogarty International Center
National Institute of Allergy and Infectious Diseases
National Institute of General Medical Sciences
Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)
(RFA-AI-24-057)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): December 4, 2024
Strategies for Eliminating HIV Proteins (R21 Clinical Trial Not Allowed)
(RFA-AI-24-064)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): December 4, 2024
Funding Opportunities
8.23.24
Notice of Special Interest (NOSI): Ending the HIV Epidemic (EHE)
(NOT-AI-24-059)
Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
(RFA-DK-25-024)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): Multiple dates, see announcement.
The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
(RFA-CA-25-011)
National Cancer Institute
Application Receipt Date(s): December 10, 2024
The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)
Funding Opportunities
8.2.24
Changes to NIH Biosketch and Other Support- NIHs Adoption of Common Forms for Biographical Sketch and Current and Pending (Other) Support by May 25, 2025
(NOT-OD-24-163)
Implementation Update for Data Management and Access Practices Under the Genomic Data Sharing Policy
(NOT-OD-24-157)
Office of the Director, NIH
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
(RFA-DA-25-024)
National Institute on Drug Abuse Application Receipt
Date(s): Multiple dates, see announcement.
Funding Opportunities
7.19.24
Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional)
(RFA-AI-24-049)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): December 4, 2024
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) (PAR-22-106)
Application due date: Multiple dates, see announcement.
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) (PAR-22-109)
Application due date: Multiple dates, see announcement.